The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
A System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,291
Functional Characterization of the S. cerevisiae Genome by Gene Deletion and Parallel Analysis
Winzeler, E. A., Shoemaker, D. D., Astromoff, A., Liang, H., Anderson, K., Andre, B., Bangham, R., Benito, R., Boeke, J. D., Bussey, H., et al. (1999) · Science · doi:10.1126/science.285.5429.901 · Cited by 3,953
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Systematic functional analysis of the Caenorhabditis elegans genome using RNAi
Kamath, R. S., Fraser, A. G., Dong, Y., Poulin, G., Durbin, R., Gotta, M., Kanapin, A., Le Bot, N., Moreno, S., Sohrmann, M., et al. (2003) · Nature · doi:10.1038/nature01278 · Cited by 3,616
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270
Systematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants
Tong, A. H. Y., Evangelista, M., Parsons, A. B., Xu, H., Bader, G. D., Pagé, N., Robinson, M., Raghibizadeh, S., Hogue, C. W. V., Bussey, H., et al. (2001) · Science · doi:10.1126/science.1065810 · Cited by 2,138
Global Mapping of the Yeast Genetic Interaction Network
Tong, A. H. Y., Lesage, G., Bader, G. D., Ding, H., Xu, H., Xin, X., Young, J., Berriz, G. F., Brost, R. L., Chang, M., et al. (2004) · Science · doi:10.1126/science.1091317 · Cited by 2,095
Protein degradation and protection against misfolded or damaged proteins.
Goldberg, A. L. (2003) · Nature · doi:10.1038/nature02263 · Cited by 2,088
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,606
Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells
Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J., & Conklin, D. S. (2002) · Genes & Development · doi:10.1101/gad.981002 · Cited by 1,552
Dolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446
The Pezcoller lecture: cancer cell cycles revisited.
Sherr, C. J. (2000) · PubMed · Cited by 1,220
Simultaneous Identification of Bacterial Virulence Genes by Negative Selection
Hensel, M., Shea, J. E., Gleeson, C., Jones, M. D., Dalton, E., & Holden, D. W. (1995) · Science · doi:10.1126/science.7618105 · Cited by 1,198
A DNA vector-based RNAi technology to suppress gene expression in mammalian cells
Sui, G., Soohoo, C., Affar, E. B., Gay, F., Shi, Y., Forrester, W. C., & Shi, Y. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082117599 · Cited by 1,104
A large-scale RNAi screen in human cells identifies new components of the p53 pathway
Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., Heimerikx, M., Kerkhoven, R. M., Madiredjo, M., Nijkamp, W., Weigelt, B., et al. (2004) · Nature · doi:10.1038/nature02371 · Cited by 1,065
(1999) · PubMed · Cited by 1,030
Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes
Ashrafi, K., Chang, F. Y., Watts, J. L., Fraser, A. G., Kamath, R. S., Ahringer, J., & Ruvkun, G. (2003) · Nature · doi:10.1038/nature01279 · Cited by 980
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells
Lee, N. S., Dohjima, T., Bauer, G., Li, H., Li, M.-J., Ehsani, A., Salvaterra, P., & Rossi, J. (2002) · Nature Biotechnology · doi:10.1038/nbt0502-500 · Cited by 953
Toward Improving Caenorhabditis elegans Phenome Mapping With an ORFeome-Based RNAi Library
Rual, J.-F., Ceron, J., Koreth, J., Hao, T., Nicot, A.-S., Hirozane-Kishikawa, T., Vandenhaute, J., Orkin, S. H., Hill, D. E., van den Heuvel, S., et al. (2004) · Genome Research · doi:10.1101/gr.2505604 · Cited by 920
Stable suppression of tumorigenicity by virus-mediated RNA interference
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00122-8 · Cited by 886
Principles for the buffering of genetic variation
Hartman, J. L., Garvik, B., & Hartwell, L. (2001) · Science · doi:10.1126/science.1056072 · Cited by 808
Principles for the Buffering of Genetic Variation
Hartman IV, J. L. (2001) · Science · doi:10.1126/science.291.5506.1001 · Cited by 808
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 796
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W., & Friend, S. H. (1997) · Science · doi:10.1126/science.278.5340.1064 · Cited by 773
A resource for large-scale RNA-interference-based screens in mammals
Paddison, P. J., Silva, J. M., Conklin, D. S., Schlabach, M., Li, M., Aruleba, S., Balija, V., O'Shaughnessy, A., Gnoj, L., Scobie, K., et al. (2004) · Nature · doi:10.1038/nature02370 · Cited by 695
Berthet, C., Aleem, E., Coppola, V., Tessarollo, L., & Kaldis, P. (2003) · Current Biology · doi:10.1016/j.cub.2003.09.024 · Cited by 663
Drug target validation and identification of secondary drug target effects using DNA microarrays
Marton, M. J., DeRisi, J. L., Bennett, H. A., Iyer, V. R., Meyer, M. R., Roberts, C. J., Stoughton, R., Burchard, J., Slade, D., Dai, H., et al. (1998) · Nature Medicine · doi:10.1038/3282 · Cited by 643
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., et al. (1995) · Nature Genetics · doi:10.1038/ng1095-210 · Cited by 627
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620
Heat shock protein 90 as a molecular target for cancer therapeutics
Isaacs, J. S., Xu, W., & Neckers, L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00029-1 · Cited by 577
Genomic profiling of drug sensitivities via induced haploinsufficiency
Giaever, G., Shoemaker, D. D., Jones, T. W., Liang, H., Winzeler, E. A., Astromoff, A., & Davis, R. W. (1999) · Nature Genetics · doi:10.1038/6791 · Cited by 570
Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569
Shoemaker, D. D., Lashkari, D. A., Morris, D., Mittmann, M., & Davis, R. W. (1996) · Nature Genetics · doi:10.1038/ng1296-450 · Cited by 569
KREK, W. (1994) · Cell · doi:10.1016/0092-8674(94)90582-7 · Cited by 492
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 466
Dobzhansky, T. (1946) · Genetics · doi:10.1093/genetics/31.3.269 · Cited by 427
Isolation of ORC6 , a Component of the Yeast Origin Recognition Complex by a One-Hybrid System
Li, J. J., & Herskowitz, I. (1993) · Science · doi:10.1126/science.8266075 · Cited by 424
Chemosensitivity linked to p73 function
Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00078-3 · Cited by 408
Self-citationDifferential regulation of E2F transactivation by cyclin/cdk2 complexes.
Dynlacht, B. D., Flores, O., Lees, J. A., & Harlow, E. (1994) · Genes & Development · doi:10.1101/gad.8.15.1772 · Cited by 395
Krek, W., Xu, G., & Livingston, D. M. (1995) · Cell · doi:10.1016/0092-8674(95)90141-8 · Cited by 354
Identification of Modulators of TRAIL-Induced Apoptosis via RNAi-Based Phenotypic Screening
Aza-Blanc, P., Cooper, C. L., Wagner, K., Batalov, S., Deveraux, Q. L., & Cooke, M. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00348-4 · Cited by 340
Caffeine-Induced Uncoupling of Mitosis from the Completion of DNA Replication in Mammalian Cells
Schlegel, R., & Pardee, A. B. (1986) · Science · doi:10.1126/science.2422760 · Cited by 320
Lu, X., & Horvitz, H. R. (1998) · Cell · doi:10.1016/s0092-8674(00)81722-5 · Cited by 315
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
Chen, Y.-N. P., Sharma, S. K., Ramsey, T. M., Jiang, L., Martin, M. S., Baker, K., Adams, P. D., Bair, K. W., & Kaelin, W. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4325 · Cited by 314
Self-citationAlmasan, A., Yin, Y., Kelly, R. E., Lee, E. Y., Bradley, A., Li, W., Bertino, J. R., & Wahl, G. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5436 · Cited by 296
Xu, M., Sheppard, K. A., Peng, C. Y., Yee, A. S., & Piwnica-Worms, H. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8420 · Cited by 293
Nghiem, P., Park, P. K., Kim, Y.-S., Vaziri, C., & Schreiber, S. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161281798 · Cited by 290
Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis
Weinstein, I. B. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.857 · Cited by 268
Role of the retinoblastoma protein in the pathogenesis of human cancer.
Sellers, W. R., & Kaelin, W. G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3301 · Cited by 253
Self-citationCombining biological networks to predict genetic interactions
Wong, S. L., Zhang, L. V., Tong, A. H. Y., Li, Z., Goldberg, D. S., King, O. D., Lesage, G., Vidal, M., Andrews, B., Bussey, H., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406614101 · Cited by 245
Synthetic enhancement in gene interaction: a genetic tool come of age
Guarente, L. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90042-g · Cited by 236
A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth
Fantin, V. R., Berardi, M. J., Scorrano, L., Korsmeyer, S. J., & Leder, P. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00082-x · Cited by 228
Cherry, S., Doukas, T., Armknecht, S., Whelan, S., Wang, H., Sarnow, P., & Perrimon, N. (2005) · Genes & Development · doi:10.1101/gad.1267905 · Cited by 226
Use of isogenic human cancer cells for high-throughput screening and drug discovery
Torrance, C. J., Agrawal, V., Vogelstein, B., & Kinzler, K. W. (2001) · Nature Biotechnology · doi:10.1038/nbt1001-940 · Cited by 226
Hall-Jackson, C. A., Cross, D. A., Morrice, N., & Smythe, C. (1999) · Oncogene · doi:10.1038/sj.onc.1203077 · Cited by 215
Stockwell, B. R., Haggarty, S. J., & Schreiber, S. L. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80004-0 · Cited by 202
DNA helicase gene interaction network defined using synthetic lethality analyzed by microarray
Ooi, S. L., Shoemaker, D. D., & Boeke, J. D. (2003) · Nature Genetics · doi:10.1038/ng1258 · Cited by 196
Altered states: selectively drugging the Hsp90 cancer chaperone
Workman, P. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.12.005 · Cited by 195
Simon, J. A., Szankasi, P., Nguyen, D. K., Ludlow, C. L., Dunstan, H. M., Roberts, C. J., Jensen, E. L., Hartwell, L. H., & Friend, S. H. (2000) · PubMed · Cited by 183
Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action
Baetz, K., McHardy, L., Gable, K., Tarling, T., Rebérioux, D., Bryan, J., Andersen, R. J., Dunn, T., Hieter, P., & Roberge, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307122101 · Cited by 177
Bender, A., & Pringle, J. R. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.3.1295-1305.1991 · Cited by 170
Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector
Parr, M. J., Manome, Y., Tanaka, T., Wen, P., Kufe, D. W., Kaelin, W. G., & Fine, H. A. (1997) · Nature Medicine · doi:10.1038/nm1097-1145 · Cited by 169
Self-citationEstablishing Genetic Interactions by a Synthetic Dosage Lethality Phenotype
Kroll, E. S., Hyland, K. M., Hieter, P., & Li, J. J. (1996) · Genetics · doi:10.1093/genetics/143.1.95 · Cited by 162
Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway
Wang, Y., Engels, I. H., Knee, D. A., Nasoff, M., Deveraux, Q. L., & Quon, K. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00113-8 · Cited by 161
Enzymatic production of RNAi libraries from cDNAs
Shirane, D., Sugao, K., Namiki, S., Tanabe, M., Iino, M., & Hirose, K. (2004) · Nature Genetics · doi:10.1038/ng1290 · Cited by 160
Oncogenes Induce and Activate Endogenous p73 Protein
Zaika, A. I., Irwin, M. S., Sansome, C., & Moll, U. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005737200 · Cited by 143
SYNTHETIC LETHALITY AND SEMI-LETHALITY AMONG FUNCTIONALLY RELATED MUTANTS OF DROSOPHILA MELANOGASTER
Lucchesi, J. C. (1968) · Genetics · doi:10.1093/genetics/59.1.37 · Cited by 139
Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics – an update
Neckers, L., & Neckers, K. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.1.137 · Cited by 137
Bailey, S. N., Sabatini, D. M., & Stockwell, B. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404425101 · Cited by 136
Fay, D. S., Keenan, S., & Han, M. (2002) · Genes & Development · doi:10.1101/gad.952302 · Cited by 135
Jonkers, J., & Berns, A. J. M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.12.002 · Cited by 133
RNAi living-cell microarrays for loss-of-function screens in Drosophila melanogaster cells
Wheeler, D. B., Bailey, S. N., Guertin, D. A., Carpenter, A. E., Higgins, C. O., & Sabatini, D. M. (2004) · Nature Methods · doi:10.1038/nmeth711 · Cited by 127
Mills, G. B., Lu, Y., & Kohn, E. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191379498 · Cited by 126
Weinstein, I. B., Begemann, M., Zhou, P., Han, E. K.-H., Sgambato, A., Doki, Y., Arber, N., Ciaparrone, M., & Yamamoto, H. (1997) · PubMed · Cited by 125
Hultsch, T., Albers, M. W., Schreiber, S. L., & Hohman, R. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6229 · Cited by 119
The Cellular Effects of E2F Overexpression
Adams, P. D., & Kaelin, W. G. (1996) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-79910-5_4 · Cited by 113
Self-citationFrom large networks to small molecules
Sharom, J. R., Bellows, D. S., & Tyers, M. (2003) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2003.12.007 · Cited by 96
Nip, J., Strom, D. K., Fee, B. E., Zambetti, G. P., Cleveland, J. L., & Hiebert, S. W. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1049 · Cited by 95
Role of E2F-1 in chemosensitivity.
Banerjee, D., Schnieders, B., Fu, J. Z., Adhikari, D., Zhao, S., & Bertino, J. R. (1998) · PubMed · Cited by 84
Choosing anticancer drug targets in the postgenomic era
Kaelin, W. G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8888 · Cited by 79
Self-citationFantin, V. R., & Leder, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0899 · Cited by 79
Characterization of synthetic DNA bar codes in Saccharomyces cerevisiae gene-deletion strains
Eason, R. G., Pourmand, N., Tongprasit, W., Herman, Z. S., Kevin, A., Jejelowo, O. A., Davis, R. W., & Štolc, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403672101 · Cited by 73
Mendoza, N., Fong, S., Marsters, J., Koeppen, H., SCHWALL, R. H., & Wickramasinghe, D. (2003) · PubMed · Cited by 71
Meng, R., Phillips∥, P. C., & El‐Deiry, W. S. (1999) · International Journal of Oncology · doi:10.3892/ijo.14.1.5 · Cited by 69
Chen, W., Lee, J., Cho, S. Y., & Fine, H. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3906 · Cited by 65
Nishimoto, T., Ishida, R., Ajiro, K., et al. (1981) · Journal of Cellular Physiology · doi:10.1002/jcp.1041090213 · Cited by 63
Haggarty, S. J., Clemons, P. A., & Schreiber, S. L. (2003) · Journal of the American Chemical Society · doi:10.1021/ja035413p · Cited by 61
RNAi and HTS: exploring cancer by systematic loss-of-function
Willingham, A. T., Deveraux, Q. L., Hampton, G. M., & Aza‐Blanc, P. (2004) · Oncogene · doi:10.1038/sj.onc.1208217 · Cited by 59
Fay, D. S., Large, E. E., Han, M., & Darland, M. R. (2003) · Development · doi:10.1242/dev.00561 · Cited by 55
Measday, V., & Hieter, P. (2002) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(02)50971-x · Cited by 48
Using cancer genetics to guide the selection of anticancer drug targets
Reddy, A., & Kaelin, W. G. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00178-9 · Cited by 46
Self-citationEstablishment of a Chemical Synthetic Lethality Screen in Cultured Human CellsPreprint
Simons, A., Dafni, N., Dotan, I., Oron, Y., & Canaani, D. (2001) · Genome Research · doi:10.1101/gr.154201 · Cited by 46
Gleevec: Prototype or Outlier?
Kaelin, W. G. (2004) · Science s STKE · doi:10.1126/stke.2252004pe12 · Cited by 33
Self-citationConsequences of Nonadaptive Alterations in Cancer
Kamb, A. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-11-0732 · Cited by 31
Emerging Uses for Genomic Information in Drug Discovery
Friend, S. H., & Oliff, A. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380211 · Cited by 30
Li, W., Su, D., Mizobuchi, H., Martin, D. S., Gu, B., Gorlick, R. G., Cole, P. D., & Bertino, J. R. (2004) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/0965040041292332 · Cited by 27
Genetic synthetic lethality screen at the single gene level in cultured human cells
Simons, A. H. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.20.e100 · Cited by 21
Mutation load, functional overlap, and synthetic lethality in the evolution and treatment of cancer
Kamb, A. (2003) · Journal of Theoretical Biology · doi:10.1016/s0022-5193(03)00087-0 · Cited by 21
Gene deletion: a new target for cancer chemotherapy
Frei, E. (1993) · The Lancet · doi:10.1016/0140-6736(93)91764-d · Cited by 19
Edgar, K. A., Belvin, M. P., Parks, A. L., Whittaker, K. L., Mahoney, M. B., Nicoll, M., Park, C. C., Winter, C. G., Chen, F., Lickteig, K., et al. (2005) · Genetics · doi:10.1534/genetics.104.036343 · Cited by 18
Cited by
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Metadata
- Authors
- Kaelin, W. G.
- Venue
- Nature Reviews Cancer
- Published
- 2005-08-19
- Volume
- 5
- Issue
- 9
- Pages
- 689-698
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2017289276
- Cited by
- 1,379
- References
- 110
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.